Nachrichten zur Gilead Sciences Aktie

Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy?

Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top…

Yescarta Label Expansion And Dividend Growth Shape Gilead Investment Case

FDA expands the label for Gilead Sciences CAR T-cell therapy Yescarta to include relapsed or refractory primary central nervous system…

Gilead Sciences Aktie: HIV-Story stützt Bewertung - Yeztugo stark, aber bereits eingepreist

Toronto (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von BMO Capital Markets:Evan Seigerman, Analyst von BMO Capital Markets, stuft die Aktie von Gilead…

Gilead Sciences Aktie: Trotz Yeztugo-Dämpfer sieht Cantor 1 Mrd. USD Potenzial

New York (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von Cantor Fitzgerald:Die Analysten von Cantor Fitzgerald stufen die Aktie von Gilead Sciences Inc.…

Gilead Sciences Stock Spikes After Q4 Results: Time to Buy?

Biotech leader Gilead Sciences (GILD) made headlines on Wednesday, with its stock spiking nearly 6% after delivering favorable Q4 results…

Gilead Sciences (GILD) Surpasses Q4 Earnings and Revenue Estimates

Gilead (GILD) delivered earnings and revenue surprises of +1.91% and +4.63%, respectively, for the quarter ended December 2025. Do the…

Gilead quarterly results beat Wall Street estimates

Gilead Sciences on Tuesday reported fourth-quarter sales and profit that came in slightly above Wall Street estimates, while its 2026…

Gilead Sciences Aktie vor Q4 2025 Zahlen: 156 oder 103 USD? Analysten-Kursziele und Ratings

Foster City (www.aktiencheck.de) - Welche Kursziele und Ratings trauen die Analysten der führenden Banken und Research-Häuser der Aktie des biopharmazeutischen…

Is Gilead Sciences (GILD) a Buy Ahead of Its Upcoming Earnings Announcement?

The companys market-leading HIV franchise has fueled top-line growth.…

Gilead Sciences (GILD) Advances While Market Declines: Some Information for Investors

In the latest trading session, Gilead Sciences (GILD) closed at $141.95, marking a +1.72% move from the previous day.…

Why Gilead Sciences (GILD) Outpaced the Stock Market Today

Gilead Sciences (GILD) reached $131.14 at the closing of the latest trading day, reflecting a +1.57% change compared to its…

Gilead Sciences (GILD) Surpasses Market Returns: Some Facts Worth Knowing

In the most recent trading session, Gilead Sciences (GILD) closed at $122.59, indicating a +1.23% shift from the previous trading…

Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates

Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences…

Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors

Gilead Sciences (GILD) concluded the recent trading session at $118.3, signifying a -2.71% move from its prior days close.…

3 Cash-Flow Machines Investors May Want Heading Into 2026

Market Analysis by covering: Gilead Sciences Inc, Qualcomm Incorporated, Exxon Mobil Corp. Read s Market Analysis on Investing.com…

Why Gilead Sciences (GILD) Dipped More Than Broader Market Today

In the latest trading session, Gilead Sciences (GILD) closed at $123.18, marking a -1.38% move from the previous day.…

Repare Therapeutics stock soars after Gilead Sciences deal for cancer drug By Investing.com

Repare Therapeutics stock soars after Gilead Sciences deal for cancer drug…

Gilead Sciences (GILD) Increases Despite Market Slip: Heres What You Need to Know

Gilead Sciences (GILD) closed the most recent trading day at $121.36, moving +2.17% from the previous trading session.…

Heres Why Gilead Sciences (GILD) is a Strong Value Stock

Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top…

Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?

GILDs HIV strength, new approvals, and rising estimates set it apart as it edges past a challenged rival in growth…

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength

…

Gilead Sciences misses on revenue guidance estimates, shares drop 4% By Investing.com

Gilead Sciences misses on revenue guidance estimates, shares drop 4%…

Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know

Gilead Sciences (GILD) concluded the recent trading session at $121.46, signifying a -2.11% move from its prior days close.…

Gilead Sciences Breaks Out To Record Highs, The Rally Has Room To Run

…

Gilead Sciences Aktie: Politik entscheidet, Q3 nur Nebengeräusch

New York (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von Cantor Fitzgerald:Cantor Fitzgerald habe das Kursziel für die Aktie von Gilead Sciences Inc.…

Gilead Sciences Aktie: Yeztugo-Start überzeugt Ärzte

New York (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse der Citigroup:Geoff Meacham, Analyst der Citigroup, habe das Kursziel für die Aktie von Gilead…

Gilead Sciences reaches settlement on Biktarvy patent litigation with generics By Investing.com

Gilead Sciences reaches settlement on Biktarvy patent litigation with generics…

Gilead Sciences (GILD) Laps the Stock Market: Heres Why

Gilead Sciences (GILD) reached $112.69 at the closing of the latest trading day, reflecting a +1.93% change compared to its…

Gilead Sciences Aktie: Droht durch Trump-Ansage ein 5%-Absturz?

Toronto (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von RBC Capital Markets:Der Analyst Brian Abrahams von RBC Capital belässt die Aktie von Gilead…

Immatics Appoints Venkat Ramanan as Chief Financial Officer

Houston, Texas and Tuebingen, Germany, October 1, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical…

Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors

Gilead Sciences (GILD) concluded the recent trading session at $110.99, signifying a -2.36% move from its prior days close.…

Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock?

Gilead surges 26.5% YTD in 2025 as HIV franchise gains momentum with Yeztugo approval, offsetting cell therapy pressures.…

Gilead Sciences: Yeztugo And Trodelvy Make This A Buy Once More

…

Gilead Sciences Aktie bleibt ein Kauf! Morgan Stanley sieht stabile Pipeline

Bad Marienberg (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse: Morgan Stanley bestätigt Kursziel 143 USDDie Analysten von Morgan Stanley haben am 21. September…

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

Gilead Sciences (GILD) concluded the recent trading session at $113.59, signifying a +1.19% move from its prior days close.…

Gilead Sciences Q2: The New Drug That Could Change Everything

…

Gilead Sciences (GILD) Tops Q2 Earnings and Revenue Estimates

Gilead (GILD) delivered earnings and revenue surprises of +3.08% and +1.95%, respectively, for the quarter ended June 2025. Do the…

Gilead posts flat quarterly profit, raises full-year outlook

Gilead Sciences on Thursday reported flat quarterly earnings on slightly higher revenue and raised its full-year financial outlook due largely…

Gilead Sciences Aktie: 140 oder 96 USD? Ziele und Ratings der Analysten vor Q2 2025 Zahlen auf einen Blick - Aktiennews

Bad Marienberg (www.aktiencheck.de) - Welche Kursziele und Ratings trauen die Analysten der führenden Banken und Research-Häuser der Aktie des biopharmazeutischen…

Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $113.03, denoting a -2.73% move from the…

Director Sells 11,136 Shares of SRRK, a Stock Up 330% in Past Year

On July 18, 2025, Director Jeffrey S. Flier disclosed the sale of 11,136 shares of Scholar Rock(NASDAQ:SRRK) in an…

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

Gilead Sciences (GILD) reached $110.17 at the closing of the latest trading day, reflecting a +1.75% change compared to its…

Gilead Sciences CFO Dickinson sells $277k in stock By Investing.com

Gilead Sciences CFO Dickinson sells $277k in stock…

Heres Why Gilead Sciences (GILD) Fell More Than Broader Market

Gilead Sciences (GILD) closed at $109.06 in the latest trading session, marking a -2.7% move from the prior day.…

Heres Why Gilead Sciences (GILD) is a Strong Momentum Stock

Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top…

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

In the most recent trading session, Gilead Sciences (GILD) closed at $113.24, indicating a +1.96% shift from the previous trading…

Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?

GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth…

Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?

Here is how Gilead Sciences (GILD) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.…